Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3182-3191

  Merchant, Melinda S ^a   Bernstein, Donna ^a   Amoako, Martha ^a   Baird, Kristin ^a   Fleisher, Thomas A ^b   Morre, Michel ^c   Steinberg, Seth M ^a   Sabatino, Marianna ^b   Stroncek, Dave F ^b   Venkatasan, Aradhana M ^b   Wood, Bradford J ^b   Wright, Matthew ^a   Zhang, Hua ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Revimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYT 107; DENDRITIC CELL VACCINE; KEYHOLE LIMPET HEMOCYANIN; RECOMBINANT INTERLEUKIN 7; UNCLASSIFIED DRUG; IL7 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERLEUKIN 7;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ANAPHYLAXIS; APHERESIS; ARTICLE; AUTOLOGOUS LYMPHOCYTE INFUSION; BLOOD AUTOTRANSFUSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DOSE RESPONSE; EMBRYONAL RHABDOMYOSARCOMA; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; FEVER; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; LYMPHOCYTOPENIA; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; OVERALL SURVIVAL; PERCUTANEOUS BIOPSY; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; SYNOVIAL SARCOMA; T LYMPHOCYTE; TREATMENT OUTCOME; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG THERAPY; IMMUNOLOGY; LEUKAPHERESIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; TRANSPLANTATION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-7; LEUKAPHERESIS; MALE; NEOPLASM RECURRENCE, LOCAL; RHABDOMYOSARCOMA; SARCOMA, EWING; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84977068146     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2550     Document Type: Article

References (47)

1. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
2. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:4148-54.
3. Potratz J, Dirksen U, Jurgens H, Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 2012;29:1-11.
4. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102.
5. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618-28.
6. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
7. Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004;22:4787-94.
8. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-6.
9. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 2010;28:3284-91.
10. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9.
11. Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol 2006;24:152-9.
12. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275-81.
13. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999;17:3487-93.
14. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:334-8.
15. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
16. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
17. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Can Res 2008;14:4850-8.
18. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Can Res 2011;17:5473-80.
19. Le Blanc K, Barrett AJ, Schaffer M, Hagglund H, Ljungman P, Ringden O, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009;15:1108-15.
20. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008;112:407-15.
21. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:1216-23.
22. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21:2227-30.
23. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Hematol 2006;134:596-601.
24. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:291-8.
25. Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant 2003;32:23-30.
26. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001;28:951-6.
27. DuBois SG, Elterman K, Grier HE. Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:351-2.
28. De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:48-52.
29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
30. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011;29:235-71.
31. Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Can Immunol Immunother 2007;56:1037-46.
32. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-61.
33. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11:1238-43.
34. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8.
35. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 2012;35:54-65.
36. Powell DJJr, Parker LL, Rosenberg SA. Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples. J Immunoth 2005;28:403-11.
37. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Can Res 2010;16:727-35.
38. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-14.
39. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113:6304-14.
40. Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, et al. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol 2001;19:3649-59.
41. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012;120:4882-91.
42. Tredan O, Menetrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronese E, et al. ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol 2015;26:1353-62.
43. Chu YW, Memon SA, Sharrow SO, Hakim FT, Eckhaus M, Lucas PJ, et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004;104:1110-9.
44. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
45. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
46. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
47. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007;120:67-74.